COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent

Menéndez, Sebastián García; Giménez, Virna Margarita Martín; Holick, Michael F.; Barrantes, Francisco J.; Manucha, Walter

doi:10.1016/j.lfs.2022.120464

Cited by 16 publications

(14 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we found a significant positive association between vitamin D deficiency and delirium risk among critically ill elderly COVID-19 patients hospitalized in ICU. In a review article, Menéndez et al concluded that vitamin D is a neuroprotective agent in COVID-19 patients that may prevent delirium in these patients 47 . However, other reasons such as APOE e4 Genotypes have been shown to be associated with an increased risk of delirium during COVID-19-related hospitalizations.…”

Section: Discussionmentioning

confidence: 99%

Vitamin D deficiency is Associated with Increased Risk of Delirium and Mortality among Critically Ill, Elderly Covid-19 Patients

Gholi¹,

Yadegarynia²,

Eini-Zeinab³

et al. 2022

Complementary Therapies in Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Vitamin D deficiency is Associated with Increased Risk of Delirium and Mortality among Critically Ill, Elderly Covid-19 Patients

Gholi¹,

Yadegarynia²,

Eini-Zeinab³

et al. 2022

Complementary Therapies in Medicine

View full text Add to dashboard Cite

“…Vitamin D might act as a strong immunosuppressant repressing cytokine release syndrome in COVID-19 via attenuating the production and secretion of crucial pro-inflammatory cytokines including NF-kB, IL-6, IL-1β, and TNF [83]. One recent review implicated that the immunomodulatory effects of vitamin D significantly reduced the level of pro-inflammatory interleukins and enhanced the synthesis of anti-inflammatory chemical mediators [84]. Taken together, supplementation with vitamin D could be an effective option to avoid the development and progression of neurodegenerative pathologies in post-COVID-19 patients.…”

Section: Clinical Practicementioning

confidence: 99%

Pharmacological Efficacy and Mechanism of Vitamin D in the Treatment of “Kidney-Brain” Disorders

Zhang¹,

Wang²,

Zhang³

2023

Vitamin D Deficiency - New Insights

View full text Add to dashboard Cite

Accumulating evidences have shown that serum 25-hydroxyvitamin D concentrations were inversely correlated with the incidence or severity of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and that vitamin D deficiency might be associated with an increased susceptibility to many of the complications accompanied by COVID-19, such as disorders in kidney and brain. Our previous experimental studies demonstrated that vitamin D and its analogs could protect from kidney diseases, neuroinflammation, and musculoskeletal disorders such as osteoporosis and muscle atrophy, through the suppressive effects on overactivation of the renin-angiotensin system (RAS) in tissues. Moreover, we published a review describing the therapeutic effects of traditional Chinese medicine (TCM) for organ injuries associated with COVID-19 by interfering with RAS. In the TCM principle “Kidney dredges brain,” this chapter will emphasize the potential preventive and therapeutic effects of vitamin D on both renal injuries and central nervous system disorders in COVID-19 patients and further elucidate the pharmacological effects with underlying mechanisms of vitamin D in “Kidney-Brain” disorders.

show abstract

“…Introduction of new drugs and advancement of potential therapies for patients with COVID-19 should be aimed at preventing COVID-19 post-infection complications such as stroke and neurodegeneration (Gholami et al 2021 ; Laudanski et al 2021 ; Menéndez et al 2022 ). One drug that might have neuroprotective effects and anti-stroke properties is minocycline (Laudanski et al 2021 ; Liu et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…New drugs and the advancement of potential therapies for patients with COVID-19 should be aimed at preventing COVID-19-induced downstream effects such as stroke and neurodegeneration (Gholami et al 2021 ; Laudanski et al 2021 ; Menéndez et al 2022 ). An important aspect of proposing drugs for the prevention and management of COVID-19-induced stroke and neurodegeneration should consider their neuroprotective role (Gholami et al 2021 ; Laudanski et al 2021 ; Menéndez et al 2022 ). Furthermore, the proposed drugs should target the underlying mechanisms of COVID-19-induced stroke and post-stroke neurological events (Gholami et al 2021a , b ; Laudanski et al 2021 ; Menéndez et al 2022 ).…”

Section: Introductionmentioning

confidence: 99%

“…An important aspect of proposing drugs for the prevention and management of COVID-19-induced stroke and neurodegeneration should consider their neuroprotective role (Gholami et al 2021 ; Laudanski et al 2021 ; Menéndez et al 2022 ). Furthermore, the proposed drugs should target the underlying mechanisms of COVID-19-induced stroke and post-stroke neurological events (Gholami et al 2021a , b ; Laudanski et al 2021 ; Menéndez et al 2022 ). To this end, candidate agents should target the MMP signaling pathway and have both anti-stroke and neuroprotective effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hypothesized neuroprotective effect of minocycline against COVID-19-induced stroke and neurological dysfunction: possible role of matrix metalloprotease signaling pathway

Shahrivar

Khakpourian²,

Majdi³

et al. 2022

Biologia

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus-2 (COVID-19) is a respiratory disease that causes dysfunction in respiration. Since late 2019, this virus has infected and killed millions of people around the world and imposed many medical and therapeutic problems in the form of a pandemic. According to recent data, COVID-19 disease can increase the risk of stroke, which can be deadly or cause many neurological disorders after the disease. During the last two years, many efforts have been made to introduce new therapies for management of COVID-19-related complications, including stroke. To achieve this goal, several conventional drugs have been investigated for their possible therapeutic roles. Minocycline, a broad-spectrum, long-acting antibiotic with anti-inflammatory and antioxidant properties, is one such conventional drug that should be considered for treating COVID-19-related stroke, as indirect evidence indicates that it exerts neuroprotective effects, can modulate stroke occurrence, and can play an effective and strategic role in management of the molecular signals caused by stroke and its destructive consequences. The matrix metalloprotease (MMP) signaling pathway is one of the main signaling pathways involved in the occurrence and exacerbation of stroke; however, its role in COVID-19-induced stroke and the possible role of minocycline in the management of this signaling pathway in patients with COVID-19 is unclear and requires further investigation. Based on this concept, we hypothesize that minocycline might act via MMP signaling as a neuroprotective agent against COVID-19-induced neurological dysfunction, particularly stroke.

show abstract

COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent

Cited by 16 publications

References 105 publications

Vitamin D deficiency is Associated with Increased Risk of Delirium and Mortality among Critically Ill, Elderly Covid-19 Patients

Vitamin D deficiency is Associated with Increased Risk of Delirium and Mortality among Critically Ill, Elderly Covid-19 Patients

Pharmacological Efficacy and Mechanism of Vitamin D in the Treatment of “Kidney-Brain” Disorders

Hypothesized neuroprotective effect of minocycline against COVID-19-induced stroke and neurological dysfunction: possible role of matrix metalloprotease signaling pathway

Contact Info

Product

Resources

About